Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + trametinib versus vemurafenib in BRAF V600E/K-mutant advanced melanoma
NL-OMON46883Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cutaneous melanoma (CM) comparing Dabrafenib + trametinib with Vemurafenib (2 arms). Primary endpoint: Overall survival. Started Sep 2012; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinibvemurafenib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON46883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46883.